01OverviewDefinition, clinical context and the essential points that orientate the chapter.
Fibroepithelial lesions contain both breast epithelium and specialised intralobular stroma. Fibroadenoma lies at the benign end of this spectrum and often produces a circumscribed, rubbery, mobile mass. Phyllodes tumours are also biphasic but show a leaf-like growth pattern and are classified as benign, borderline or malignant by histological features. The clinical challenge is that imaging and a limited core can overlap, particularly in a rapidly enlarging or stromally cellular lesion.
Management therefore starts with concordance rather than a size label. If the history, examination, imaging and core all support a simple fibroadenoma, observation avoids an unnecessary scar and distortion. If growth is substantial, the appearance is atypical, the pathology says cellular fibroepithelial lesion or phyllodes cannot be excluded, or the patient has important symptoms or concern, the case needs breast multidisciplinary review. The team chooses repeat representative sampling or excision and plans the operation so a possible phyllodes tumour is not inadvertently fragmented.
Key points
- A fibroadenoma is a benign biphasic lesion containing epithelial and stromal elements; it commonly presents as a well-defined mobile mass in a younger patient.
- Rapid enlargement, large size, older age at presentation or imaging-pathology discordance raises concern for a phyllodes tumour or another diagnosis, even when a previous core suggested fibroadenoma.
- Triple assessment must be concordant: the clinical mass, radiological target and sampled tissue should describe the same lesion and support the same benign explanation.
- Core biopsy may report a cellular fibroepithelial lesion because limited tissue cannot reliably separate cellular fibroadenoma from phyllodes tumour; that uncertainty requires specialist review rather than false reassurance.
- A small, stable, clinically and radiologically concordant fibroadenoma can often be managed without surgery, with advice to return for growth or change.
- A growing cellular fibroepithelial lesion in which phyllodes cannot be excluded has a low threshold for intact diagnostic surgical excision; vacuum-assisted fragmentation is not the recommended route for that problem.
02AetiologyUnderlying causes, associations and risk factors, with why each one matters.
Hormone-responsive stroma
Fibroadenoma arises from terminal duct-lobular stromal and epithelial elements and is more common during hormonally active years; lesions may enlarge in pregnancy or with exogenous hormonal stimulation.
Phyllodes stromal neoplasia
Phyllodes tumour is a fibroepithelial neoplasm in which the stromal component drives biological behaviour; histological grade reflects features including stromal atypia, mitoses, overgrowth and tumour borders.
03PathophysiologyThe causal sequence from the underlying abnormality to symptoms and harm.
- 1Biphasic proliferation
Coordinated epithelial and stromal growth forms a circumscribed mass. In fibroadenoma this usually remains orderly, whereas phyllodes develops exaggerated intracanalicular leaf-like architecture.
- 2Heterogeneous stromal behaviour
Cellularity and atypia can vary within one lesion, explaining why a small core may show fibroadenoma-like tissue while a more active region supports phyllodes classification.
- 3Local expansion and recurrence
Phyllodes tumours can expand quickly and recur locally when biologically aggressive tissue remains. Malignant forms can spread haematogenously, particularly to lung, rather than following usual nodal carcinoma patterns.
04Clinical features and red flagsSymptoms, examination findings, patterns of presentation and time-critical warnings.
A firm, smooth, well-circumscribed and mobile mass in a younger patient is characteristic, but palpation cannot establish histology. Lesions may become more noticeable during pregnancy or hormonal stimulation and may regress after menopause.
Documented rapid or continued enlargement should trigger reassessment of the original target and biopsy. Growth may still occur in fibroadenoma, yet it increases the practical difficulty of excluding phyllodes tumour or sampling heterogeneous stroma.
Phyllodes tumour often presents as a painless enlarging breast mass and can become very large, stretch the skin or create visible veins. Nodal enlargement is uncommon from haematogenous sarcoma-like spread, so palpable nodes require assessment rather than assumption.
Pain, anxiety, functional interference, pregnancy plans and concern about breast contour matter after diagnostic safety has been established. Patient preference can support removal, but it should follow a balanced explanation of scars, contour change and recurrence uncertainty.
05InvestigationsWhat to request, why it matters and how to interpret it.
Read from the initial assessment onwards. Tests may run in parallel in urgent care; first-line, preferred, confirmatory, definitive and gold-standard labels appear only when the chapter explicitly states them.
- 01
Targeted ultrasoundFirst step - Why
- Characterise a palpable fibroepithelial lesion and provide a route for representative needle sampling.
- Interpretation and limitations
- A parallel, oval, circumscribed hypoechoic mass supports fibroadenoma but is not pathognomonic. Heterogeneity, clefts, internal cystic spaces or interval growth may increase concern, while comparison must use the same lesion and dimensions.
- 02
Age-appropriate mammography - Why
- Assess the wider breast and identify calcification, distortion or features not fully shown by ultrasound.
- Interpretation and limitations
- A circumscribed mass can be benign, and involuting fibroadenomas may develop coarse calcification. Mammography does not reliably separate fibroadenoma from phyllodes tumour, so morphology must be correlated with the clinical trajectory and tissue.
- 03
Image-guided core biopsy - Why
- Sample epithelial and stromal architecture when imaging or clinical features require tissue diagnosis.
- Interpretation and limitations
- A definite benign fibroadenoma result is useful when representative and concordant. A cellular fibroepithelial lesion, stromal atypia or wording that phyllodes tumour cannot be excluded signals a limitation of the core and prompts multidisciplinary planning.
- 04
Radiology-pathology concordance review - Why
- Decide whether the tissue diagnosis adequately explains lesion morphology, size and growth.
- Interpretation and limitations
- Discordance is present when a benign core does not account for an enlarging, heterogeneous or suspicious target. Re-review, repeat larger-volume sampling or excision may be needed; merely repeating the benign label does not resolve target uncertainty.
06Differential diagnosisRealistic alternatives and the features that help distinguish them.
Simple breast cyst
A cyst may feel mobile and circumscribed but ultrasound demonstrates fluid characteristics; complicated or complex appearances require assessment rather than assumption from palpation.
Phyllodes tumour
Rapid growth, larger size, heterogeneity and cellular stromal histology raise concern, although no single clinical or imaging feature reliably distinguishes phyllodes from fibroadenoma.
Circumscribed carcinoma
Mucinous, papillary or other carcinomas may appear relatively smooth. Older age, discordant morphology or suspicious tissue features prevent reassurance from a well-defined border.
07ManagementImmediate care, first-line treatment, alternatives and escalation.
01Assessment pathwayManage a new circumscribed breast massFirst stepA 24-year-old presents with a 2 cm mobile breast mass that has not changed over four months and has no skin, nipple or nodal abnormality.+
- 1DefinitiveMap the lump clinically and ask about growth, pregnancy, hormone exposure, previous masses and family history, while avoiding a definitive benign label from mobility alone.
- 2Arrange targeted imaging; if ultrasound shows a classic benign mass, decide with the breast team whether age, appearance and local protocol require core confirmation.
- 3When clinical and imaging findings, plus pathology if obtained, are concordant for fibroadenoma, explain that removal is not automatically required and discuss observation against symptoms and preference.
- 4Record the lesion coordinates and baseline size, give explicit advice to return for enlargement, fixation or new skin or nipple change, and verify that any planned review has a named route.
02Indeterminate fibroepithelial pathwayExcise a growing lesion that may be phyllodes intactA 41-year-old has a 4.8 cm mass that enlarged over three months; core histology reports a cellular fibroepithelial lesion with phyllodes tumour not excluded.+
- 1Treat the pathology wording as genuine diagnostic uncertainty and confirm that imaging, measured growth and the sampled area all refer to the same lesion.
- 2Discuss the case at the breast multidisciplinary meeting; rapid growth and a cellular fibroepithelial core create a low threshold for diagnostic surgical excision rather than further reassurance.
- 3Plan intact surgical excision with orientation so the pathologist can assess lesion borders and margins. Vacuum-assisted excision is not recommended for this large growing cannot-exclude-phyllodes lesion because fragmentation impairs assessment.
- 4Keep this pathway separate from a previously confirmed concordant fibroadenoma that later grows: that lesion needs renewed concordance assessment, but growth alone does not automatically prove phyllodes tumour.
03Post-excision pathwayUse final histology to close the loopExcision histology unexpectedly identifies a phyllodes tumour rather than the presumed fibroadenoma.+
- 1Confirm the tumour grade, size, margin status and whether the specimen remained intact, then correlate the pathology with the preoperative imaging extent.
- 2Return the result to a specialist multidisciplinary team rather than applying invasive breast carcinoma nodal algorithms to a fibroepithelial tumour.
- 3Apply the 2025 ABS margin recommendations by grade: benign tumours need complete excision with an intact capsule; borderline tumours aim for 5 mm, require re-excision below 3 mm, and at 3 to under 5 mm use shared discussion of re-excision versus surveillance; malignant tumours aim for 10 mm, require re-excision below 5 mm, and at 5 to under 10 mm re-excision is recommended, with surveillance reserved for selected patients after discussion.
- 4Give the patient a written follow-up plan that identifies local recurrence symptoms and separates breast review from any additional malignant-phyllodes staging decision.
08ComplicationsImportant consequences, why they occur and why they matter clinically.
Progressive distortion
A large benign fibroadenoma or expanding phyllodes tumour can stretch skin, displace normal tissue and make later breast-conserving excision cosmetically difficult.
Local phyllodes recurrence
Residual tumour at an inadequate margin can contribute to local recurrence; risk and surveillance differ by histological grade and final operative-pathology assessment.
Malignant distant spread
Malignant phyllodes tumour can metastasise through the bloodstream, most often involving lung or other distant sites, while nodal metastasis is much less characteristic.
09Monitoring and follow-upTreatment response, safety checks and longer-term review.
- For an observed fibroadenoma, retain the original side, clock position, maximum dimensions and imaging descriptor so reported growth can be checked against the same target.
- Reassess sooner if the mass enlarges, becomes less mobile, causes skin stretching or pain, or no longer matches the original benign imaging explanation.
- After removal, review wound healing, haematoma, infection, altered sensation and contour as well as the final pathology and concordance decision.
- Use the ABS grade- and operation-specific schedule. Benign phyllodes uses patient-initiated follow-up without routine imaging. Borderline disease uses clinical review every 6 months for 3 years; after breast-conserving surgery add index-quadrant ultrasound every 6 months for 3 years and annual mammography for 5 years, while after mastectomy do not perform routine breast imaging. Malignant disease uses clinical review every 6 months for 3 years then annually in years 4 and 5; after breast-conserving surgery add index-quadrant ultrasound every 6 months for 3 years and annual mammography for 5 years, while after mastectomy do not perform routine breast imaging. Obtain chest imaging every 6 months for 2 years then annually in years 3 to 5 for malignant phyllodes.
10Special situationsVariants, exceptions and circumstances that change the usual approach.
Core limitation is biological
Fibroadenoma and phyllodes can share heterogeneous stromal features. A core samples only part of a biphasic lesion, so uncertainty may persist despite technically adequate tissue and does not necessarily indicate poor pathology practice.
Follow-up depends on grade and operation
Malignant phyllodes surveillance includes chest imaging because metastatic spread is usually haematogenous. Local ultrasound and mammography apply after breast-conserving surgery, whereas routine imaging of a mastectomy side is not recommended.
Pregnancy can expose growth
Hormonal stimulation may enlarge a fibroadenoma during pregnancy. Rapid change still merits reassessment because physiology does not prove that the lesion is unchanged biologically, and timing of intervention needs obstetric coordination.
Excision has trade-offs
Removing a benign lesion can relieve symptoms or uncertainty, but it also creates scar, volume loss and possible asymmetry. Shared decision making should include observation when diagnostic concordance makes it safe.
11Common pitfallsFrequent interpretation and management errors.
- 01
Calling every mobile mass a fibroadenoma ignores cysts, phyllodes tumour and circumscribed malignancies that can feel similarly smooth.
- 02
Assuming a previous benign core remains decisive despite rapid interval growth fails to account for sampling error and lesion heterogeneity.
- 03
Using size alone as an automatic operation threshold without considering growth, concordance, symptoms and patient preference oversimplifies management.
- 04
Treating phyllodes tumour like invasive ductal carcinoma can lead to unnecessary axillary surgery and an inappropriate follow-up plan.